Astria Therapeutics
ATXS
ATXS was delisted on the 22nd of January, 2026.
33 hedge funds and large institutions have $81.4M invested in Astria Therapeutics in 2015 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 12 increasing their positions, 11 reducing their positions, and 6 closing their positions.
9% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 11
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
3% less capital invested
Capital invested by funds: $83.7M → $81.4M (-$2.31M)
6% less funds holding
Funds holding: 35 → 33 (-2)
33% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FAM
Fred Alger Management
New York
|
+$1.26M |
| 2 |
Northern Trust
Chicago,
Illinois
|
+$310K |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$240K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$141K |
| 5 |
DM
Deerfield Management
New York
|
+$120K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$1.97M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$325K |
| 3 |
Millennium Management
New York
|
-$305K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$176K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$103K |
ATXS Hedge Fund Activity: Q4 2015 in Review
33 of the 3,813 institutional investors tracked by Wall St. Rank reported a position in Astria Therapeutics (ATXS) for Q4 2015, worth a combined $81.4M — down 2.8% from $83.7M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of ATXS and 4 opened new positions — a net loss of 2 holders — while 11 trimmed existing stakes and 12 added.
The largest buyer was Fred Alger Management, opening a new position worth an estimated $1.26M. The largest seller was Sphera Funds Management, cutting an estimated $1.97M.
- 33 institutional investors held Astria Therapeutics (ATXS) as of Q4 2015, down from 35 in Q3 2015.
- Funds reported $81.4M of Astria Therapeutics stock for Q4 2015, down 2.8% quarter-over-quarter.
- 4 funds opened new Astria Therapeutics positions in Q4 2015 and 6 closed out, a net change of -2 holders.
- The largest Astria Therapeutics buyer in Q4 2015 was Fred Alger Management, an estimated $1.26M added.
- The largest Astria Therapeutics seller in Q4 2015 was Sphera Funds Management, an estimated $1.97M sold.
Based on aggregated 13F filings for Q4 2015.